Reata Pharmaceuticals Inc RETA

NAS: RETA | ISIN: US75615P1030   25/09/2023
172,36 USD (+0,02%)
(+0,02%)   25/09/2023

8 januari 2024 · Kirby McInerney LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of Reata Pharmaceuticals, Inc. Common Stock · Persbericht

18 maart 2023 · REATA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc. - RETA · Persbericht

17 februari 2022 · RETA LAWSUIT ALERT: Levi & Korsinsky Notifies Reata Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline · Persbericht

16 februari 2022 · RETA Investors Have Opportunity to Lead Reata Pharmaceuticals, Inc. Securities Fraud Lawsuit · Persbericht

10 februari 2022 · RETA LAWSUIT ALERT: Levi & Korsinsky Notifies Reata Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline · Persbericht

4 februari 2022 · REATA PHARMACEUTICALS, INC. (NASDAQ: RETA) SHAREHOLDER CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Reata Pharmaceuticals, Inc. (NASDAQ: RETA) · Persbericht

2 februari 2022 · RETA LAWSUIT ALERT: Levi & Korsinsky Notifies Reata Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline · Persbericht

31 januari 2022 · Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Reata Pharmaceuticals, Inc. (RETA) · Persbericht

13 januari 2022 · Reata Pharmaceuticals SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Reata Pharmaceuticals, Inc. - RETA · Persbericht

6 januari 2022 · REATA PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Reata Pharmaceuticals, Inc. - RETA · Persbericht

30 december 2021 · RETA Investors Have Opportunity to Lead Reata Pharmaceuticals, Inc. Securities Fraud Lawsuit · Persbericht

30 december 2021 · REATA PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Reata Pharmaceuticals, Inc. - RETA · Persbericht

8 december 2021 · RETA INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals, Inc. (RETA) Investors to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations · Persbericht

1 maart 2021 · Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results and Provides an Update on Clinical Development Programs · Persbericht

1 maart 2021 · Reata Pharmaceuticals, Inc. Submits NDA for Company’s Lead Program: Bardoxolone in Alport Syndrome · Persbericht

22 februari 2021 · Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2020 Financials and to Provide an Update on Development Programs on March 1, 2021 · Persbericht

Mijn selecties